Accelerating scale up and commercialisation of 100% bacteria free eggs for use in production of vaccines

Introduction

Ovagen is aiming to transform the egg-based production of vaccines and other biopharmaceutical medicines by producing the world's first Germ Free egg and bringing it into mass production.

Project Background

The proposed programme of work will build on the groundwork initiated as part of the 30-month OvaVax project (GA 858390). This project provides a logical expansion of this disruptive, innovative technology to address the challenges facing the world as it deals with COVID-19 and future pandemics, particularly the need for rapid scale-up of vaccine production.

Funding Application

Ovagen is applying for EIC Accelerator funding to broaden the project scope of their existing H2020 SME Instrument Phase 2. The goals include:

1. Expanding and accelerating the existing influenza project.
2. Including additional diseases such as:
   • COVID-19
   • Yellow Fever
   • Newcastle Disease
3. Ensuring readiness for production and accelerated international scale-up of germ-free egg production.

Objectives

The ultimate aim is to increase global vaccine manufacturing capacity in preparation for future pandemics similar to COVID-19.